ReShape Lifesciences Inc
NASDAQ:RSLS
ReShape Lifesciences Inc
Operating Income
ReShape Lifesciences Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
Operating Income
-$14.6m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Operating Income
$2.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
Boston Scientific Corp
NYSE:BSX
|
Operating Income
$2.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Stryker Corp
NYSE:SYK
|
Operating Income
$4.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
Abbott Laboratories
NYSE:ABT
|
Operating Income
$6.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Operating Income
$1.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
See Also
What is ReShape Lifesciences Inc's Operating Income?
Operating Income
-14.6m
USD
Based on the financial report for Dec 31, 2023, ReShape Lifesciences Inc's Operating Income amounts to -14.6m USD.
What is ReShape Lifesciences Inc's Operating Income growth rate?
Operating Income CAGR 5Y
17%
Over the last year, the Operating Income growth was 46%. The average annual Operating Income growth rates for ReShape Lifesciences Inc have been -11% over the past three years , 17% over the past five years .